Postoperative atrial fibrillation after cardiac surgery

Postoperative atrial fibrillation (POAF) remains one of the most common complications after coronary artery bypass grafting, valve surgery and combined cardiac procedures. It often appears between the second and fourth postoperative days, when inflammation, atrial stretch, autonomic activation, electrolyte shifts and withdrawal of chronic medicines converge. Although frequently transient, POAF can prolong hospitalisation, increase stroke risk, complicate rehabilitation and place additional pressure on perioperative cardiac services.

Predicting who will develop the arrhythmia and selecting an appropriate prophylactic amiodarone strategy require more than applying a single risk score. Clinicians must balance the expected reduction in atrial tachyarrhythmia against bradycardia, hypotension, QT prolongation, drug interactions and organ toxicity. This balance is especially important in Australia, where care spans high-volume metropolitan centres in Sydney and Melbourne, regional hospitals and rural referral pathways with different monitoring resources.

Why postoperative atrial fibrillation develops

Cardiac surgery creates a temporary substrate for atrial arrhythmia. Pericardial and atrial manipulation, cardiopulmonary bypass, ischaemia–reperfusion injury and the systemic inflammatory response can alter conduction and refractoriness. Atrial oedema and stretch promote conduction heterogeneity, while sympathetic activation and catecholamine exposure increase triggered activity. Fluid shifts, anaemia, hypoxaemia, fever and electrolyte depletion can amplify these effects.

The incidence varies with the operation and the population studied. POAF develops in roughly 20–40% of patients after isolated coronary surgery and may occur in 40–60% after valve or combined procedures, although contemporary enhanced recovery pathways may change observed rates. Episodes may terminate spontaneously, but recurrence, rapid ventricular response and haemodynamic instability can require rate control, rhythm restoration or temporary pacing.

The consequences extend beyond the arrhythmia itself. POAF is associated with longer intensive care and ward stays, increased use of anticoagulation, and a greater risk of readmission. It can delay mobilisation and discharge planning, particularly when a patient lives several hours from a tertiary centre. In Australia, this matters for people transferred between metropolitan hospitals and regional services, where continuity of ECG review and medication monitoring may be less immediate.

Predictors that should shape risk assessment

Age is among the most consistent predictors, reflecting atrial fibrosis, impaired relaxation and a greater burden of cardiovascular disease. Previous atrial fibrillation, left atrial enlargement, left ventricular dysfunction, heart failure, hypertension, diabetes, chronic kidney disease and chronic obstructive pulmonary disease also identify patients with a more vulnerable atrial substrate. Male sex, obesity and sleep-disordered breathing may add further risk, although their predictive value varies between cohorts.

Operative factors are equally relevant. Valve surgery, combined procedures, emergency operations, longer cardiopulmonary bypass time and aortic cross-clamp duration are commonly associated with POAF. Postoperative sepsis, bleeding, transfusion, renal injury, hypokalaemia and hypomagnesaemia can act as modifiable triggers. A history of thyroid disease is particularly important when amiodarone is being considered, because both unrecognised thyroid dysfunction and antiarrhythmic toxicity can complicate recovery.

Risk scores can support structured assessment but should not replace clinical judgement. A patient with modest baseline risk may still develop POAF after a prolonged, inflammatory operation, while a high-risk patient may remain in sinus rhythm with careful perioperative management. Preoperative review should include the medication list, baseline ECG, renal and hepatic function, chest history, thyroid status when clinically indicated, and any prior exposure to amiodarone or other QT-prolonging medicines.

Prevention begins with correcting reversible factors. Maintaining potassium and magnesium within the local protocol range, treating hypoxia and infection, controlling pain, avoiding unnecessary catecholamine exposure and resuming beta-blockade when safe are practical measures. Early mobilisation and sleep protection also support recovery. These interventions are especially useful in busy Australian units, where discharge targets and bed availability can create pressure to distinguish a brief, stable episode from clinically significant recurrent AF.

Where amiodarone fits in prophylaxis

Amiodarone is effective because it acts across several ion-channel pathways and can reduce the incidence of supraventricular tachyarrhythmia after cardiac surgery. Trials and meta-analyses have evaluated oral, intravenous and combined regimens, with protocols ranging from preoperative loading to postoperative initiation. One commonly cited approach uses a short oral course before surgery followed by continuation after the operation, while other pathways begin intravenous treatment in the operating theatre or intensive care unit.

The best regimen depends on timing, procedure, local protocols and the patient’s haemodynamic profile. Preoperative loading may be practical for planned surgery, but it is less suitable when the operation is urgent or when there is insufficient time for monitoring. Postoperative intravenous administration offers rapid exposure but can worsen hypotension or bradycardia, particularly alongside beta-blockers, opioids and sedatives. Oral conversion is generally preferred once gastrointestinal absorption and haemodynamic stability are reliable.

Amiodarone should usually be considered alongside, rather than instead of, beta-blocker prophylaxis. Continuing a pre-existing beta-blocker, unless contraindicated, has a strong role in reducing sympathetic triggers. For patients at high risk of POAF who cannot tolerate beta-blockade, amiodarone may be a reasonable alternative or additional intervention. Sotalol and other strategies may be used in selected settings, but renal function, QT interval and institutional experience limit their applicability.

The choice should be documented as a risk–benefit decision rather than an automatic response to age or procedure type. Atrial enlargement, previous AF and valve surgery may favour prophylaxis, while marked sinus-node disease, advanced atrioventricular block, severe lung disease, prolonged QT or significant liver or thyroid concerns may argue for a different approach. The special collections available through the Journal of Arrhythmia can help clinicians compare evolving evidence and protocol designs.

Monitoring safety during treatment

Before administering amiodarone, clinicians should review the ECG for bradycardia, conduction disease and QT prolongation. Potassium and magnesium should be corrected, and interacting medicines should be identified. The risk of bradycardia rises when amiodarone is combined with beta-blockers, non-dihydropyridine calcium-channel blockers or digoxin. Warfarin exposure may increase, while the interaction with direct oral anticoagulants requires careful consideration of renal function, bleeding risk and the specific product information.

Short perioperative courses are less likely to cause pulmonary, hepatic or thyroid toxicity than prolonged outpatient treatment, but a short course is not risk-free. Intravenous administration can cause hypotension, phlebitis and acute bradyarrhythmia. Liver enzymes may rise, and patients with pre-existing interstitial lung disease require particular caution. If treatment continues after discharge, a clear stop date and monitoring plan should be recorded rather than allowing amiodarone to persist by default.

Temporary epicardial pacing wires can provide an important safety net when bradycardia occurs, although pacing dependence and wire removal must be considered before discharge. Continuous telemetry is appropriate during the highest-risk period, with escalation for sustained AF, haemodynamic compromise, chest pain, syncope or a rapid ventricular response that does not settle with initial treatment. Melbourne and Sydney tertiary hospitals may have rapid electrophysiology support, whereas regional teams may need an agreed transfer and telehealth pathway.

Australian prescribing must also account for Therapeutic Goods Administration product information, hospital formulary restrictions and the Pharmaceutical Benefits Scheme when medication is continued outside hospital. Clear communication between the cardiac surgeon, cardiologist, pharmacist, general practitioner and cardiac rehabilitation team is essential. Patients should receive practical advice about dose changes, pulse monitoring, adverse effects and the need to report breathlessness, fainting, visual symptoms or signs of thyroid dysfunction.

From prevention to an integrated rhythm pathway

Prophylaxis does not eliminate POAF, so every cardiac surgical service needs a treatment pathway. Stable patients may receive rate control, correction of triggers and observation, while persistent or symptomatic AF may require pharmacological or electrical cardioversion. Amiodarone can support rhythm control in selected patients, but its use should be reassessed if the arrhythmia persists beyond the immediate postoperative period.

Anticoagulation decisions require an individual assessment of stroke risk, bleeding, recent surgery and the expected duration of AF. A brief episode in the early postoperative period does not automatically create the same long-term indication as established recurrent AF. Conversely, recurrent or sustained arrhythmia, prior embolic disease or substantial baseline risk may justify specialist review and a defined anticoagulation plan. The decision and review date should be visible in the discharge summary.

Follow-up should confirm whether sinus rhythm has been maintained, whether amiodarone has been stopped, and whether a longer-term diagnosis of atrial fibrillation is emerging. Ambulatory monitoring can be useful when symptoms are intermittent or when anticoagulation decisions remain uncertain. Education should reflect everyday Australian life: a patient returning to work in Brisbane, travelling from Perth to a regional community or resuming lawn maintenance and walking in Adelaide may notice palpitations only during exertion, making symptom-triggered review important.

The broader electrophysiology literature also shows why postoperative rhythm management should remain connected to advances in autonomic modulation and acute arrhythmia care. The Journal of Arrhythmia’s discussion of stellate ganglion blockade illustrates how targeted autonomic interventions are being explored in severe arrhythmic settings, although such techniques are not routine prophylaxis for uncomplicated POAF.

A practical protocol should therefore combine baseline risk assessment, continuation of appropriate beta-blockade, electrolyte and trigger management, selective amiodarone, continuous monitoring and a documented discharge plan. Institutions should audit POAF incidence, amiodarone exposure, bradycardia, cardioversion, readmission and anticoagulation duration. Those data can reveal whether prophylaxis is benefiting the intended population or exposing lower-risk patients to avoidable treatment.

Clinicians, researchers and trainees can follow the developing evidence through the Journal of Arrhythmia, including research on perioperative prevention, postoperative monitoring and rhythm-control strategies. Applying that evidence through locally agreed pathways can reduce variation between hospitals while preserving the clinical judgement required for complex surgical patients.